SCHEMBL29951201

SCHEMBL29951201

Cc1ccc(F)c(B(O)O)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.33
P2RX7 Q99572 2/20 0.31
TNF P01375 1/20 0.31
RIPK1 Q13546 1/20 0.31
ADRA2A P08913 1/20 0.30
CLCN2 P51788 1/20 0.30
CYP3A4 P08684 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3319716 1.00 ENPP2 (0.33) ENPP2P2RX7TNFRIPK1ADRA2A
SCHEMBL29956143 0.82 TNF (0.39) ENPP2TNFRIPK1
SCHEMBL5422266 0.78 ALDH1A1 (0.42) ENPP2CLCN2CYP3A4
SCHEMBL29955010 0.78 TNF (0.36) ENPP2TNFRIPK1CYP3A4
SCHEMBL15609444 0.78 ACHE (0.32) ACHE
SCHEMBL29952822 0.78 ALDH1A1 (0.42) ENPP2CLCN2CYP3A4
SCHEMBL28136581 0.78 ACHE (0.32) ACHE
SCHEMBL21543102 0.77 ALDH1A1 (0.37) ACHE
SCHEMBL29955796 0.77 MAPK1 (0.39) ENPP2TNFRIPK1CYP3A4
SCHEMBL29491113 0.77 ALDH1A1 (0.37) ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499612-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2025-02-05 EP disclosed
CN-118974020-A Substituted 3-aminoindazole derivatives as kinase inhibitors 内尔维亚诺医疗科学公司 2024-11-15 CN disclosed
WO-2023186773-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-10-05 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed